UNSPSC 51172117: Aseripide

This classification denotes an antispasmotic agent with the molecular formula C26H30FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2M24F1I2A, chemically known as (2r,4r)-3-(n-((3-((s)-1-carboxyethyl)phenyl)carbamoyl)glycyl)-2-(o-fluorophenyl)-4-thiazolidinecarboxylic acid, 4-tert-butylester but generally known as aseripide, which bears US NIH Compound Identifier 179339. European Medicines Agency schedules Aseripide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05580MIG.

UNSPSC 51172117 Aseripide (Commodity) covers offender specimen collection and drug testing services for criminal justice supervision and corrections departments, encompassing immunoassay and confirmatory testing (LC/MS/MS or GC/MS), collection-site staffing, interactive voice response randomization systems, alternative testing methodologies including oral fluid and hair analysis, and electronic result reporting. State and local corrections and community supervision agencies issue solicitations under this code; Collin County Community Supervision and Corrections Department represents the primary recent buyer. Work is performed at fixed collection locations with defined hours and staffing requirements, and vendors must maintain SAMHSA, state-level (such as TX DPS), or CAP laboratory certification. Testing volumes and panel configurations (five-panel and six-panel immunoassays with confirmatory testing) are specified in advance, and pricing is standardized on a per-test basis across three service models (screening only, confirmation after screening, or screening with automatic confirmation).

Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services on September 25, 2026, with an original response deadline of July 23, 2026 (a backward-facing date suggesting a posting error in the source); the anticipated award date is August 10, 2026. The contract scope covers two collection sites in Plano and McKinney with approximately 25,031 annual tests and an estimated value of $600,000 over an initial two-year term with three optional one-year renewals. The evaluation emphasizes vendor qualifications and client references (40 points combined), along with understanding and cost (30 points each), with optional Phase 2 demonstrations and interviews worth up to 30 additional points. Funding derives from Texas Department of Criminal Justice appropriations. The county reserves the right to award in whole or in part to multiple vendors, and price redetermination is limited to annual cost-of-living adjustments capped at 3.0 percent based on the medical Consumer Price Index.